We shouldn't assume a lack of benefit in certain groups.
For those living with the most relentless form of multiple sclerosis, medicine has long offered little more than the counsel of endurance. A major international trial published in The Lancet this week suggests that ocrelizumab — already used in earlier-stage disease — can meaningfully slow the advance of disability even in patients once considered beyond the reach of treatment, reducing progression risk by 30 percent and preserving the hand function that patients themselves identified as their most precious remaining independence. The ORATORIO-HAND study, spanning 22 countries and more than 1,000 patients, quietly redraws the boundary of who deserves a chance.
- People with advanced primary progressive MS have had no approved treatment options, leaving them to watch their independence erode without medical recourse.
- The trial deliberately enrolled patients previously excluded from research — those over 55, those already in wheelchairs — confronting the field's long habit of studying only those easiest to help.
- Ocrelizumab cut the risk of wheelchair dependency by 52 percent in patients who could still walk, and reduced hand and arm decline by 41 percent — the very function patients said mattered most to their dignity.
- Among patients showing active brain inflammation at baseline, the drug reduced progression risk by 55 percent, suggesting the treatment's power is sharpest where biological activity remains.
- The findings now press NHS decision-makers and neurologists to reconsider who qualifies for access, and challenge the entire field to measure treatment success by what patients actually value losing.
For people living with primary progressive multiple sclerosis, the options have always been thin. This form of the disease worsens steadily without remission, and doctors have long questioned whether treating advanced cases — patients already dependent on wheelchairs — could make any real difference. A major international trial published this week in The Lancet suggests the answer is yes.
The ORATORIO-HAND study, coordinated by Queen Mary University of London, tracked more than 1,000 patients across 22 countries. What distinguished it was its inclusivity: where previous trials excluded patients over 55 or those with severe disability, this one enrolled people up to age 65, many already substantially impaired. The researchers wanted to know whether treatment could still matter for people with nowhere left to go but down.
The numbers suggest it can. Patients receiving ocrelizumab showed a 30 percent lower risk of disability progression compared to placebo. The drug reduced hand and arm function decline by 41 percent, and cut the risk of eventually needing a wheelchair by 52 percent in patients who could still walk. Where active brain inflammation was present, the benefit reached a 55 percent reduction in progression risk.
Those figures were shaped by a deliberate choice about what to measure. When researchers asked people with advancing MS what they most wanted to preserve, the answer was not walking — it was hand function. The ability to groom oneself, to manage toileting, to perform the small physical acts that separate dignity from dependence. The 9-Hole Peg test became a central outcome measure. It delivered.
Ocrelizumab is already prescribed for relapsing MS and early progressive disease. These findings could extend its use to advanced PPMS patients who currently have no approved options. Lead author Gavin Giovannoni framed the result as a shift in perspective: neurologists should no longer assume that advanced disease places patients beyond benefit. The question now is how quickly this evidence translates into access — and whether those who have waited longest will be the next to receive care.
For people living with primary progressive multiple sclerosis, the options have always been thin. This form of the disease, which accounts for one in every ten MS cases, worsens steadily over time without the remission periods that mark other variants. Doctors have long debated whether treating advanced cases—patients already struggling with mobility, already dependent on wheelchairs—could actually help. A major international trial published this week in The Lancet suggests the answer is yes.
The ORATORIO-HAND study, coordinated by Queen Mary University of London, tracked more than 1,000 patients across 22 countries over months of treatment with ocrelizumab, a drug already in use for other forms of MS. What made this trial different was whom it included. Previous major studies typically excluded patients over 55 or those with severe disability. This one enrolled people up to age 65, many of them already substantially impaired, some already using wheelchairs. The researchers wanted to know whether treatment could still matter for people with nowhere left to go but down.
The numbers suggest it can. Patients who received ocrelizumab showed a 30 percent lower risk of disability progression compared to those given placebo. More strikingly, the drug reduced the decline in hand and arm function by 41 percent at the 12-week mark. For patients who had not yet lost the ability to walk, ocrelizumab cut the risk of eventually needing a wheelchair by 52 percent. In patients whose baseline brain scans showed signs of active inflammation, the benefit was even larger—a 55 percent reduction in progression risk.
These numbers matter because they measure something that previous trials often overlooked. Researchers working with Gavin Giovannoni, the study's lead author, surveyed people with advancing MS and asked what they most wanted to preserve. The answer was not walking. It was hand function. Independence in grooming, in toileting, in the small physical acts that separate dignity from dependence. The 9-Hole Peg test, which measures how quickly someone can move pegs in and out of holes, became a central measure of whether the drug was working. It was.
The implications ripple outward. Ocrelizumab is already prescribed for active relapsing MS and early primary progressive disease. These findings could expand its use to people with advanced PPMS who currently have no approved treatment options at all. On the NHS, where treatment decisions are carefully rationed, the trial suggests a rethinking of who deserves access. More broadly, it challenges how the field measures success. If a drug preserves hand function in someone who will lose the ability to walk anyway, is that a failure or a victory? This study argues it is a victory.
Giovannoni framed the finding as a shift in perspective. "We shouldn't assume a lack of benefit in certain groups," he said. The study, he added, changes how neurologists should think about managing advanced MS. The MS Society, in response, emphasized the human stakes: many people with progressive disease describe it as debilitating and unpredictable. A treatment that slows that progression, that keeps hands working and independence intact, addresses something fundamental. The question now is how quickly these findings move from published research into clinical practice, and whether patients with advanced disease will gain access to a drug that the evidence suggests can help them.
Citações Notáveis
Treatment can make a meaningful difference to people with more advanced forms of MS and can help preserve hand and arm function, which is important for maintaining independence and quality of life.— Gavin Giovannoni, lead author and Professor of Neurology at Queen Mary University of London
Hand and arm function is essential for helping people to remain independent. Many previous trials have focused solely on walking ability, but trials like this are vital in helping us find treatments for everyone.— Dr. Catherine Godbold, MS Society
A Conversa do Hearth Outra perspectiva sobre a história
Why does this trial matter so much when ocrelizumab already exists and is already being used?
Because it was being used only in certain populations—people early in their disease, people under a certain age. The assumption was that if you were already in a wheelchair or over 55, treatment wouldn't help you anymore. This trial proves that assumption wrong.
But the improvements are modest, aren't they? Thirty percent lower risk of progression—that's not a cure.
No, it's not a cure. But for someone with advanced MS, the difference between needing a wheelchair in two years versus three years, or between losing hand function in six months versus ten months, is the difference between independence and dependence. That's not modest to the person living it.
The study specifically measured hand function. Why was that the focus?
Because when researchers actually asked people with progressive MS what mattered most to them, they said hand function. Not walking. Hands. The ability to feed yourself, to use a toilet, to hold something. That's what determines whether you can live at home or need full-time care.
Does this mean everyone with advanced MS should get ocrelizumab now?
That's what the NHS and other health systems will have to decide. The trial shows it works. But there are always questions about cost, about who benefits most, about how to implement it fairly. The evidence is there now. The policy has to catch up.
What about the patients who were in the placebo group? Did they know they might be getting a placebo?
They did—that's how clinical trials work. But yes, there's a real ethical weight to that when you're talking about people with progressive disease. That's partly why this trial is significant. It shows the benefit was real enough that the field can now move forward with confidence.